However, PIK3CA inhibitors as targeted drugs for treating KTS have potential efficacy.[19] These inhibitors can block abnormal vascular formation and proliferation, alleviate vascular and tissue overgrowth, potentially alleviating symptoms and improving disease prognosis in patients, and even reversing vascular remodeling. Here, PIK3CA is linked to angioosteohypertrophic syndrome.